Guardant Health partners with actor James Van Der Beek to promote early colorectal cancer screening through the Shield blood ...

Diagnostics company Guardant Health (NASDAQ:GH) in Q2 CY2025, with sales up 30.9% year on year to $232.1 million. The company ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its partnership with actor and ...

James Van Der Beek was diagnosed with colon cancer in 2023. He hopes more people will get screened earlier with the new ...

Second Quarter 2025 Results Key Financial Results Revenue: US$232.1m (up 31% from ...

With rates of colorectal cancer (CRC) surging among younger populations, Guardant Health is turning to a famous face beloved ...

James Van Der Beek and Guardant are partnering for a campaign focused on colorectal cancer. Guardant Health announced a ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

James Van Der Beek, whose net worth is $6 million, as per Celebrity Net Worth, has partnered with Guardant Health to raise ...

Discover Guardant Health's FDA breakthroughs & revenue growth! Learn why profitability-focused investors might hold back ...

Guardant Health has commercially launched Guardant360 ®, Guardant360 ® CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer patients ...

Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and ...